41 results on '"Cutaia, Ornella"'
Search Results
2. Fourteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT) on Cancer Bio-Immunotherapy, Siena, Italy, October 13–15, 2016
3. Table S1 from Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases
4. Fig.S1 from Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases
5. Fig S2 from Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases
6. “Cancer Bio-Immunotherapy in Siena”: Thirteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 8–10, 2015
7. “Cancer Bio-Immunotherapy in Siena”: Twelfth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 9–11, 2014
8. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial
9. Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study
10. CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy?
11. “Cancer Bio-Immunotherapy in Siena”: Eleventh Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 17–19, 2013
12. ICOS Expression as Immunologic Marker in Immune Activating Monoclonal Antibodies
13. Tenth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), SIENA, Italy, November 5–7, 2012
14. Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme
15. Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases
16. Primary analysis and four-year follow-up of the phase III NIBIT-M2 trial in melanoma patients with brain metastases
17. 844 Immunomodulatory activity of epigenetic drugs combinations in mesothelioma: laying the ground for new immunotherapeutic strategies
18. Abstract 4488: Immunomodulatory activity of epigenetic drugs: Laying the ground for new combined immunotherapeutic strategies for glioblastoma
19. Circulating Levels of PD-L1 in Mesothelioma Patients from the NIBIT-MESO-1 Study: Correlation with Survival
20. Guadecitabine Plus Ipilimumab in Unresectable Melanoma: The NIBIT-M4 Clinical Trial
21. Epigenetic Immune Remodeling of Mesothelioma Cells: A New Strategy to Improve the Efficacy of Immunotherapy.
22. NK- and T-cell subsets in malignant mesothelioma patients : Baseline pattern and changes in the context of anti-CTLA-4 therapy
23. Safety and immunobiological activity of guadecitabine sequenced with ipilimumab in metastatic melanoma patients: The phase Ib NIBIT-M4 study.
24. NK‐ and T‐cell subsets in malignant mesothelioma patients: Baseline pattern and changes in the context of anti‐CTLA‐4 therapy
25. Immunomodulatory Properties of DNA Hypomethylating Agents: Selecting the Optimal Epigenetic Partner for Cancer Immunotherapy
26. Abstract CT059: Epigenetic tumor remodelling to improve the efficacy of immune checkpoint blockade: the NIBIT-M4 clinical trial
27. Fourteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT) on Cancer Bio-Immunotherapy, Siena, Italy, October 13–15, 2016
28. Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients
29. 'Cancer Bio-Immunotherapy in Siena': Thirteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 8-10, 2015.
30. Fourteenth Meeting of the <italic>Network Italiano per la Bioterapia dei Tumori (NIBIT)</italic> on Cancer Bio-Immunotherapy, Siena, Italy, October 13-15, 2016.
31. Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study
32. SRC Family Kinase Inhibition Through a New Pyrazolo[3,4-d]Pyrimidine Derivative as a Feasible Approach for Glioblastoma Treatment
33. Abstract LB-228: Pharmacokinetics of Tremelimumab, a fully human anti-CTLA-4 monoclonal antibody, in subjects with unresectable malignant mesothelioma
34. CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy?
35. “Cancer Bio-Immunotherapy in Siena”: Eleventh Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 17–19, 2013
36. A phase 2 single-arm study with tremelimumab at an optimized dosing schedule in second-line mesothelioma patients.
37. A phase II study of intratumoral application of L19IL2/L19TNF in melanoma patients in clinical stage III or stage IV M1a with presence of injectable cutaneous and/or subcutaneous lesions.
38. Immune correlates of metastatic melanoma patients treated with ipilimumab in combination with fotemustine in the phase II NIBIT-M1 study
39. Expression and regulation of B7‐H3 immunoregulatory receptor, in human mesothelial and mesothelioma cells: Immunotherapeutic implications
40. CD40 Expression by Human Melanocytic Lesions and Melanoma Cell Lines and Direct CD40 Targeting With the Therapeutic Anti-CD40 Antibody CP-870,893
41. ICOS Expression as Immunologic Marker in Immune Activating Monoclonal Antibodies.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.